Table 3.
Cox Analysis of BM IPFS
| BM IPFS (pBM Group) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||||||
| HR | 95% CI | p value | HR | 95% CI | p value | |||
| Down | Up | Down | Up | |||||
| Age (≥70 vs <70) | 1.67 | 0.496 | 5.618 | 0.408 | ||||
| Histologic type | ||||||||
| Adeno vs Squamous | 1.753 | 0.404 | 7.602 | 0.453 | ||||
| Adeno vs Other | 0.989 | 0.638 | 1.535 | 0.962 | ||||
| ICIs line, ≥3 vs <3 | 2.225 | 1.071 | 4.621 | 0.032* | 1.441 | 0.624 | 3.332 | 0.393 |
| ECOG PS, 2 vs 0–1 | 4.485 | 2.153 | 9.346 | <0.001* | 3.247 | 1.448 | 7.283 | 0.004* |
| Size of intracranial lesion (maximum diameter) (≥3cm vs <3cm) | 0.451 | 0.159 | 1.282 | 0.135 | ||||
| Edema size (≥3cm vs <3cm) | 0.474 | 0.183 | 1.227 | 0.124 | ||||
| Number of total lesions | 1.2 | 0.621 | 2.32 | 0.588 | ||||
| Meningeal metastasis | 2.13 | 0.95 | 4.776 | 0.066 | ||||
| GPA score | ||||||||
| 0–1 vs 1.5–2.5 | 0.924 | 0.396 | 2.157 | 0.856 | ||||
| 0–1 vs 3 | 0.036 | 0 | 15,824 | 0.615 | ||||
| Combined with radiotherapy (yes vs no) | 0.697 | 0.36 | 1.346 | 0.282 | ||||
| ICIs regimes (monotherapy vs combined therapy) | 0.386 | 0.196 | 0.759 | 0.006* | 0.629 | 0.277 | 1.425 | 0.266 |
| Mutation (EGFR mutation vs other mutation) | 1.051 | 0.643 | 1.718 | 0.842 | ||||
| WBRT (yes vs no) | 0.794 | 0.399 | 1.582 | 0.512 | ||||
| SRS (yes vs no) | 0.794 | 0.328 | 1.919 | 0.608 | ||||
| Liver metastasis | 1.328 | 0.316 | 5.580 | 0.699 | ||||
| Gender, n (%) (male vs female) | 0.957 | 0.449 | 2.04 | 0.910 | ||||
Abbreviations: ICIs, immune checkpoint inhibitors; DS-GPA, disease-specific graded prognostic assessment; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; pBM, patients with brain metastasis prior to ICIs treatment. *p<0.05.